Quentin Blackford, President and CEO, iRhythm : Yeah. So I think on the FDA side, I would say good progress. I feel as good as I have with the FDA since the whole sort of ordeal of the 483s, the initial warning letter sort of came about. And this whole question of MCT and your clinical technicians, are they part of the product or are they not? We aligned with them very clearly in the mid part of last year, and I think from that point forward we've done a tremendous job of addressing their concerns.